Glycopeptide and uses thereof

Abstract

A glycolipopeptide comprising a carbohydrate component, a peptide component and a lipid component, for use as a therapeutic or prophylactic vaccine. Also provided are monoclonal and polyclonal antibodies that recognize the glycolipopeptide of the invention, as well as uses thereof.

1 . A method for making an antibody comprising:
 injecting into a mammal a glycolipopeptide comprising:
 at least one carbohydrate component comprising a B-epitope; 
 at least one peptide component comprising a T-epitope; and 
 at least one lipid component; 
 wherein the carbohydrate component comprises a saccharide selected from the group consisting of N-acetylglucosamine (GlcNAc), N-acetylgalactosamine (GalNAc), mannose, fucose and glucose; and 
   isolating from the mammal at least one antibody that binds to the glycolipopeptide.   
     
     
         2 .- 21 . (canceled) 
     
     
         22 . An antibody made according to the method of  claim 1 . 
     
     
         23 . A method for making an antibody comprising:
 injecting into a mammal a glycolipopeptide comprising:
 at least one carbohydrate component comprising a B-epitope; 
 at least one peptide component comprising a T-epitope; and 
 at least one lipid component; 
 wherein the carbohydrate component comprises a saccharide selected from the group consisting of N-acetylglucosamine (GlcNAc), N-acetylgalactosamine (Ga1NAc), mannose, fucose and glucose; 
   harvesting cells from the mammal;   fusing the cells with myeloma cells to form hybridomas;   selecting at least one hybridoma producing an antibody which binds to the glycolipopeptide; and   isolating the antibody.   
     
     
         24 . The method of  claim 23  wherein the cells are spleen cells or lymph cells. 
     
     
         25 . The method of  claim 23 , wherein the carbohydrate component comprises a self-antigen comprising the B-epitope. 
     
     
         26 . The method of  claim 25 , wherein the self-antigen comprises a MUC-1 glycopeptide. 
     
     
         27 . The method of  claim 23 , wherein the lipid component comprises Pam 3 CysSK n , wherein n=0, 1, 2, 3, 4, or 5. 
     
     
         28 . The method of  claim 23 , wherein the peptide component comprises a microbial peptide comprising the T-epitope. 
     
     
         29 . An antibody made according to the method of  claim 23 . 
     
     
         30 . A method for detecting, diagnosing or monitoring an infection, disease or disorder in a subject, the method comprising:
 contacting a biological sample from the subject with the antibody of  claim 29 ; and   detecting binding of the antibody to a component in the biological sample;   
       wherein binding of the antibody to a sample component is indicative of the presence of the infection, disease or disorder in the subject. 
     
     
         31 . The method of  claim 30  further comprising:
 quantitating the level of antibody binding to the sample component; 
 quantitating the level of antibody binding to components in a comparable non-diseased sample; and 
 comparing the binding levels; 
 wherein a change in antibody binding in the biological sample compared to the non-diseased sample is indicative of the presence of the infection, disease or disorder in the subject. 
 
     
     
         32 . A method for detecting a glycosylated protein comprising:
 contacting a biological sample with the antibody of  claim 29 ; and   detecting binding of the antibody to the protein.   
     
     
         33 . The method of  claim 32  further comprising identifying the protein. 
     
     
         34 . A method for identifying a protein associated with a disease state comprising:
 contacting a first biological sample associated with a disease state with the antibody of  claim 29 ;   contacting a second biological sample associated with different disease state or no disease with said antibody;   detecting binding of said antibody to glycosylated proteins in the first and second samples; and   identifying glycosylated proteins that are enriched in one sample compared to the other;   
       wherein a difference in the amount of a glycosylated protein in the two samples is indicative of a protein associated with a disease state. 
     
     
         35 . The method of  claim 34  further comprising identifying the protein associated with a disease state. 
     
     
         36 . A method for making an antibody comprising:
 injecting into a mammal a glycolipopeptide comprising:   at least one carbohydrate component comprising a B-epitope;   at least one peptide component comprising a T-epitope; and   at least one lipid component;   wherein the carbohydrate component comprises a monosaccharide or a disaccharide;   harvesting cells from the mammal;   fusing the cells with myeloma cells to form hybridomas;   selecting at least one hybridoma producing an antibody which binds to the glycolipopeptide; and   isolating the antibody.   
     
     
         37 . The method of  claim 36 , wherein the cells are spleen cells or lymph cells. 
     
     
         38 . The method of  claim 36 , wherein the carbohydrate component comprises a self-antigen comprising the B-epitope and wherein the lipid component comprises Pam 3 CysSK n , wherein n=0, 1, 2, 3, 4, or 5. 
     
     
         39 . The method of  claim 36 , wherein the peptide component comprises a microbial peptide comprising the T-epitope. 
     
     
         40 . An antibody made according to the method of  claim 36 .